肺癌恶性胸腔积液胸腔镜下胸腔内循环灌注化疗临床分析 |
| |
引用本文: | 邢军,陆辉辉,李文韬,赖习华. 肺癌恶性胸腔积液胸腔镜下胸腔内循环灌注化疗临床分析[J]. 医学临床研究, 2012, 29(5): 902-904,908 |
| |
作者姓名: | 邢军 陆辉辉 李文韬 赖习华 |
| |
作者单位: | 邢军 (湖南中医药高等专科学校附属第一医院心胸外科,湖南,株洲,412000) ; 陆辉辉 (湖南中医药高等专科学校附属第一医院心胸外科,湖南,株洲,412000) ; 李文韬 (湖南中医药高等专科学校附属第一医院心胸外科,湖南,株洲,412000) ; 赖习华 (湖南中医药高等专科学校附属第一医院心胸外科,湖南,株洲,412000) ; |
| |
摘 要: | [目的]探讨胸腔镜辅助下胸腔内循环灌注化疗(TICPC)治疗肺癌恶性胸腔积液(MPG)的方法和疗效.[方法]将2004年5月至2008年3月期间80例肺癌MPG患者随机分为治疗组(A组,40例)和对照组(B组,40例).A组在全身麻醉胸腔镜下行胸膜活检术,并胸腔内恒温43℃生理盐水3000 mL加顺铂300 mg灌注1 h;B组予胸腔引流,胸腔内灌注顺铂80~100 mg.比较两组治疗前后胸水量的变化,胸水中癌胚抗原(CEA)、乳酸脱氨酶(LDH )、腺苷脱氨酶(ADA)浓度的变化和不良反应.[结果]A、B组有效率分别为87.5%和57.5%,差异有统计学意义(P〈0.05).A、B两组治疗后胸水中LDH较治疗前明显上升(P〈0.05),CEA均较治疗前明显下降(P〈0.05),且A组较B组更为显著(P〈0.05).两组治疗前后各种不良反应比较差异无统计学意义(P〉0.05).[结论]TICPC 治疗肺癌 MPG创伤小、视野大,能直视下分离粘连,并准确对胸膜病变活检,具有较高的临床应用价值.
|
关 键 词: | 肺肿瘤/并发症 胸腔积液/治疗 胸腔镜检查 |
Clinical Analysis of Thoracoscopic Intrapleural Circular Perfusion Chemotherapy for the Treatment of Malignant Pleural Effusion Caused by Lung Cancer |
| |
Affiliation: | XING Jun, LU Hui-hui, LI Wen-tao, et al ( Department of Cardiothoracic Surgery, Affiliated First Hospital, Hunan Traditional Chinese Medicine College, Hunan 412000, China ) |
| |
Abstract: | [Objective] To explore the method and efficacy of thoracoscopic intrapleural circular perfusion ehemotherapy(TICPC) for the treatment of malignant pleural effusion (MPE) caused by lung cancer. [Methods]Totally 80 patients with MPE caused by lung cancer from May 2004 to March 2008 were randomly divided into treatment group(group A, n=40) and control group(group B, n=40). Treatment group under-went pleural biopsy under general anesthesia and received intrapleural perfusion with 3000mL normal saline un-der 43℃ constant temperature and 300mg eisplatin. Group B underwent chest drainage and intrapleural perfu-siGn with 80-100mg cisplatin. The change of pleural fluid volume, carcinoembryonic antigen(CEA), lactic dehydrogenase(LDH) and adenosine deaminase(ADA) in pleural fluid and side effects were compared before and after the treatment. [Results] The effective rate in group A and B was 87.5% and 57.5% respectively, and there was significant difference( P〈0.05). Compared with before treatment, CEA in pleural fluid in two groups obviously decreased( P〈0.05), and CEA in group A decreased more significantly than group B( P〈0.05). There was no significant difference in side effects in two groups between before and after treatment( P〉0.05). [Conclusion] TICPC for the treatment of MPE caused by lung cancer has small wound and wide visu-al field, and can separate the adhesion under direct vision, and undergo pleural biopsy, so it has high clinical value, |
| |
Keywords: | Lung neoplasms/CO pleural effusion/TH thoracoscopy |
本文献已被 维普 等数据库收录! |
|